Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 724

Showing 1-25 of 724 citing articles:

Triple negative breast cancer: Pitfalls and progress
Paola Zagami, Lisa A. Carey
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 286
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
Jae Young So, Joyce E. Ohm, Stan Lipkowitz, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108253-108253
Open Access | Times Cited: 112
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Eleonora Nicolò, Federica Giugliano, Liliana Ascione, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102395-102395
Closed Access | Times Cited: 111
Spatial predictors of immunotherapy response in triple-negative breast cancer
Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, et al.
Nature (2023) Vol. 621, Iss. 7980, pp. 868-876
Open Access | Times Cited: 111
Precision Medicine: Disease Subtyping and Tailored Treatment
Richard Wang, Zhixiang Wang
Cancers (2023) Vol. 15, Iss. 15, pp. 3837-3837
Open Access | Times Cited: 101
Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
Shengnan Sha, Luyi Si, Xinrui Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 97
Advances in immunotherapy for triple-negative breast cancer
Yang Liu, Yueting Hu, Jinqi Xue, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 97
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 90
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
Nadine S. van den Ende, Anh H. Nguyen, Agnes Jager, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2969-2969
Open Access | Times Cited: 88
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 87
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
Qin Wu, Yan Nie, Wail Ba-alawi, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 8, pp. 821-830
Open Access | Times Cited: 85
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer
Xueqi Ou, Yeru Tan, Jindong Xie, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101063-101063
Open Access | Times Cited: 67
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1210-1229
Open Access | Times Cited: 55
FOXM1: A small fox that makes more tracks for cancer progression and metastasis
Md Arafat Khan, Parvez Κhan, Aatiya Ahmad, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 1-15
Open Access | Times Cited: 50
A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
Hitesh Kumar, Neha Gupta, Rupshee Jain, et al.
Journal of Advanced Research (2023) Vol. 54, pp. 271-292
Open Access | Times Cited: 49
Role of Immunotherapy in Breast Cancer
Saya Jacob, Laura A. Huppert, Hope S. Rugo
JCO Oncology Practice (2023) Vol. 19, Iss. 4, pp. 167-179
Open Access | Times Cited: 48
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
Hatem Soliman, Deanna Hogue, Hyo S. Han, et al.
Nature Medicine (2023)
Open Access | Times Cited: 48
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Uğur Uslu, Tong Da, Charles‐Antoine Assenmacher, et al.
Science Advances (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 41
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
Carmine Valenza, Beatrice Taurelli Salimbeni, Celeste Santoro, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 767-767
Open Access | Times Cited: 37
The anticancer mechanism of action of selected polyphenols in triple-negative breast cancer (TNBC)
Reyhaneh Farghadani, Rakesh Naidu
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115170-115170
Open Access | Times Cited: 37
Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
Boya Lu, Elango Natarajan, Hanumantha Rao Balaji Raghavendran, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 36
Dendritic Cells in Cancer Immunology and Immunotherapy
Laura Hato, Ángel Vizcay Atienza, Iñaki Eguren, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 981-981
Open Access | Times Cited: 27
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Icro Meattini, Carlotta Becherini, Saverio Caini, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 2, pp. e73-e83
Open Access | Times Cited: 24
Towards targeting the breast cancer immune microenvironment
Michael A. Harris, Peter Savas, Balaji Virassamy, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 554-577
Closed Access | Times Cited: 22
Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer
Sicong Huang, Ting Wen, Jiachen Wang, et al.
Acta Biomaterialia (2024) Vol. 176, pp. 344-355
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top